先进急诊医学

经导管动脉化疗栓塞术联合贝伐珠单抗+信迪利单抗治疗老年不可切除中晚期肝细胞癌

彭 文举

郑州大学第五附属医院

DOI: https://doi.org/10.59429/xjjz.v8i1.13447

Keywords: 肝细胞癌；经导管动脉化疗栓塞术；信迪利单抗；贝伐珠单抗；老年患者

---

Abstract

目的：探讨经导管动脉化疗栓塞术（TACE）联合贝伐珠单抗与信迪利单抗治疗不可切除中晚期肝细胞癌（HepatocellularCarcinoma，HCC）患者的疗效及安全性。方法：回顾性分析 2024 年 1 月至 2025 年 6 月于我院接受治疗的 80 例不可切除中晚期 HCC 患者的临床资料，根据治疗方案分为联合组（40 例，采用 TACE 联合贝伐珠单抗 + 信迪利单抗治疗）和 TACE 组（40 例，单纯采用 TACE 治疗）。比较两组患者的客观缓解率（ORR）、疾病控制率（DCR）及不良反应发生情况。结果：联合组患者的 ORR（35.50%vs15.50%，P<0.05）和 DCR（62.50%vs37.50%，P<0.05）显著高于 TACE 组；两组患者不良反应发生率比较，差异无统计学意义（P>0.05），联合组主要新增不良反应为蛋白尿（17.50%）和高血压（22.50%），多为Ⅰ - Ⅱ级，经对症处理后可缓解。结论：TACE 联合贝伐珠单抗与信迪利单抗治疗老年不可切除中晚期 HCC 疗效显著，安全性可控，可作为临床优选方案。

---

References

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2024; 74(3):229-263.

[2] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南 (2024 年版 ). 肿瘤综合治疗电子杂志 2024; 10(3):17-68.

[3] Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Frontiers in Immunology 2022; 13.

[4] Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treatment Reviews 2020; 86.

[5] Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. The Lancet Oncology 2021; 22(7):977-990.

[6] Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. Journal of Hepatology 2020; 72(2):288-306.

[7] Yao C, Wu S, Kong J, Sun Y, Bai Y, Zhu R, et al. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies. Cancer Biology & Medicine 2023; 20(1):25-43.

[8] 李金娥，周彬，唐德为等. 原发性肝癌的免疫治疗研究进展及面临的挑战. 癌症进展 2024; 22(12):1281-1287.

[9] Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nature Reviews Clinical Oncology 2018; 15(5):325-340.

[10] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine 2020; 382(20):1894-1905.

[11] Yang F, Xu G-L, Huang J-T, Yin Y, Xiang W, Zhong B-Y, et al. Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response. Frontiers in Immunology 2022.